Background. Number of patients needed to treat (NNT) with a statin in primary prevention of coronary heart disease (CHD) is often misinterpreted because this single statistic averages results from heterogeneous studies. Objective. To provide estimates of the number of individuals needed to be prescribed a statin to prevent one CHD event accounting for their level of CHD risk and for persistence to treatment. Methods. A post hoc analysis was conducted based on a Cochrane review on statins for the primary prevention of cardiovascular diseases. Five-year NNTs were calculated separately from randomized clinical trials (RCTs), including 'lower' and 'higher' risk populations (CHD mean event rates of 3.7 and 14.4 per 1000 person-years, respectively). NNTs were adjusted for 5-year persistence to treatment using a value of 65%. Results. Persistence-adjusted 5-year NNTs to prevent one CHD for the lower and higher CHD risk categories were 146 [95% confidence interval (CI): 117-211] and 53 (95% CI: 39-88) respectively, values 25% and 15% higher than their unadjusted counterpart (117, 95% CI: 94-167 and 46, 95% CI: 34-78). Conclusions. Five-year NNTs for statins to prevent a first CHD is almost three times higher in those at lower versus higher risk populations. Reporting combined results from RCTs including subjects at different cardiovascular risks should be avoided. Individualizing the risk of CHD should orient family physicians and their patients in their choice of preventive approaches and generate more realistic expectations about compliance and outcomes.
Introduction
Number needed to treat (NNT) is often used in medical publications to translate complex research results into a simple metric easy to interpret and use in medical decision making. For instance, a 5-year NNT of 88 is interpreted as the estimated number of patients needed to be treated with statins over 5 years to prevent the occurrence of a first coronary heart disease (CHD) event (1) . Although generally acknowledged, the actual impact of lower persistence to statin treatment in real-life compared with research populations from which NNT values are derived has not been adequately accounted for in NNT estimations (2) (3) . As the effectiveness of interventions to improve persistence to statins has been shown to be modest, it is imperative that clinicians, patients and decision makers have access to the right information, so they can base their treatment and health policy decisions on realistic expectations (4) (5) .
We hypothesize that an NNT of 88 derived from meta-analysis of randomized clinical trials (RCTs) of statins for primary cardiovascular (CV) prevention does not reflect the true number of individuals needed to be prescribed a statin to prevent a first CHD event, because it includes populations at different CV risks with diverse outcomes, and because the drop-out rate from treatment is higher in real-life than in RCTs (6) (7) . The objective of this study was to provide estimates of the 5-year number of individuals needed to be prescribed a statin to prevent a first non-fatal or fatal myocardial infarction (MI) or CHD death accounting for their level of CHD risk and for real-life persistence to statin treatment in primary care.
Methods
This post hoc analysis used the results of nine RCTs included in a Cochrane meta-analysis of statins for the primary prevention of CV disease, that specifically reported outcomes on fatal and non-fatal MI and CHD deaths (supplementary Table) (6) . CHD outcomes based on symptoms (angina and unstable angina) and coronary revascularization were excluded from this analysis as they may not have been uniformly defined and systematically reported between RCTs (i.e. 'soft' outcomes) (8) . The nine RCTs were classified in two broad CHD-risk categories labelled 'lower' and 'higher', primarily based on the ranking of CHD event rates observed in the control group of each RCT. The ranking showed a gap between the ACAPS study with an event rate of 6.9 per 1000 person-years (p-y) and the KAPS study with a rate of 12.6 per 1000 p-y, which was used to delineate our two categories (Table 1) . The PHYLLIS study (event rate of 4.6 per 1000 p-y) was reclassified in the higher CHD risk category because it included only patients with uncontrolled or untreated hypertension. The number of CHD events (fatal and non-fatal MI, and CHD deaths) in statin and control groups for each RCT were entered in a meta-analysis table stratified by the two CHD risk categories using Review Manager (RevMan) version 5.3 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014).
Five-year NNTs were calculated separately for each of the nine RCTs. Incidence rates of CHD events in control groups were calculated as the total number of CHD events divided by the number of p-y of observation in each RCT. The number of p-y of follow-up was estimated, when not reported, using the number of study subjects included and the average duration of follow-up reported. NNTs were calculated using CHD incidence rates in statin and control groups as a valid approximation of the cumulative incidence as recommended when incidence rates are low (9) . NNTs were calculated for 5-year utilization of statins, which is consistent with the duration of follow-up in the RCTs (range 31 to 64 months), in compliance with the recommendation of not extrapolating NNTs beyond the actual period of observation (10) . The adjustment for persistence with statin treatment in RCTs compared to a real-life population was calculated (11) by multiplying each NNT by the ratio of the average persistence rate of study subjects with their statin treatment in the RCT over a 5-year persistence of 65% derived from a cohort of 27 5363 new lipid-lowering-drug users (92.4% statins) followed from 2010 to 2015 through the Quebec National Drug Insurance database that covers almost all individuals over the age of 65 (12) . In that cohort, persistence, defined as the number of individuals who filled a statin prescription 5 years after their initial prescription, was equal to 66.3%. This result is consistent with what is reported elsewhere (2), (7) . Numbers used and details for NNT calculations are 
+7 (+15%)
CHD, coronary heart disease; CVD, cardiovascular diseases; F, female; HBP, high blood pressure and SBP, systolic blood pressure; M, male; MI, myocardial infarction; NNT, number needed to treat; NR, not reported; p-y, person-years of follow-up; NS, not statistically significant results; RCT, randomized controlled trial; T-Chol, total cholesterol and LDL-C, LDL cholesterol in mmol/l; wgt, weighted.
a Classification in higher and lower CV risk by the presence or not of symptomatic CHD at inclusion and/or CV-risk factors as inclusion criteria; studies ordered by incidence of CHD (non-fatal and fatal MI and CHD death) event rates in control groups.
b
All values correspond to population means unless otherwise indicated.
c CHD events include non-fatal and fatal myocardial infarction and CHD death.
d NNT calculated using the formula: {1/[Incidence rate in controls -(incidence rate in controls × risk ratio)]} /5; Risk ratios and 95% confidence intervals obtained from the meta-analysis table (Figure 1 ). e All NNT calculated for an equivalent 5 years.
f Average persistence to treatment reported; subgroup summary using mean weighted by the number of p-y in the subgroup.
g Adjusted NNT = unadjusted NNT × (% persistence to treatment/65%); see Methods. Table 1 .
Continued
shown in Table 1 and footnotes. Data extraction and calculations were performed independently by two of the authors and discrepancies were resolved by consensus.
Results
Four of the nine RCTs included in this analysis were classified in the 'lower CHD risk' category (13-16) with CHD event rates in the control group all below 7.0 per 1000 p-y, and five in the 'higher CHD risk' category (17-21) with rates above 12.0 per 1000 p-y except for the PHYLLIS study (17) that included, as previously mentioned, only patients with uncontrolled or untreated hypertension (Table 1) . Summary risk ratios (RR) used in the calculation of 5-year NNTs and their 95% confidence intervals (CI) stratified by the two CHDrisk categories are displayed in Figure 1 . Based on I 2 statistics, RR were homogeneous within but not between the two categories. Table 1 shows 5-year unadjusted and adjusted NNTs calculated for each RCT and their summary for the two CHD-risk categories. Individual adjusted NNTs were larger than their corresponding unadjusted values by 25% and 15% on average in the lower and higher CHD risk categories, respectively. Larger adjusted NNT values mean a less effective treatment, a result that is explained by the better average persistence to statin treatment in RCTs (81% and 74% in the higher and lower CHD risk categories, respectively) compared to our 5-year estimation of 65% in a real-life population.
As expected, 5-year NNTs were larger in the lower CHD risk category. The difference was almost 3-folds with a summary value for persistence-adjusted NNT of 146 (95% CI: 117-211) (unadjusted: 117; 95% CI: 94-167) compared to the higher CHD risk category with a summary value of 53 (95% CI: 39-88) (unadjusted: 46; 95% CI: 34-78). Larger NNT values in the lower CHD risk category reflect lower summary CHD event rate in that category (3.7 per 1000 p-y) compared to the higher CHD risk category (14.4 per 1000 p-y).
Discussion
Our study highlights concerns about estimating NNT from studies including different CV-risk populations. In our analysis, NNTs were almost three times larger in populations at lower than at higher CHD risk because of associated CV-risk factors. In addition, it showed that the unadjusted NNT with a statin to prevent one CHD event inappropriately underestimates the number of patients to prescribe a statin. Differences between adjusted and unadjusted NNTs reflect in part the gap between persistence to statin treatment in the RCTs retained in this analysis (62% to 98%) and that observed in real-life populations.
These more realistic and appropriate results regarding the use of statins in primary prevention of CHD should send a strong signal to physicians, patients and decision makers. Firstly, in absolute numbers, our results estimate that 1 out of 146 lower risk individuals (1 out of 53 of higher risk patients), who are prescribed a statin for primary prevention, experiences a CHD benefit over 5 years while no benefit is to be expected in the other 145 (52 in higher risk individuals). Thus, in the lower CHD risk populations, the perspective of benefit is very modest over a 5-year period. These figures concur to qualifying an intervention such as statin prescription in a population at low CV risk, as a pseudo-prevention strategy (22) . In fact, our 95% CI for persistence-adjusted NNT values in the lower risk group (117 to 211) is well within the range of values reported in a recent review of eight meta-analyses on the number needed to harm with regard to the risk of new-onset diabetes with statins (23) . Balancing this kind of harm against the benefits expected in individuals at low CV risk may lead to reconsider statin use and put more emphasis on lifestyle management instead.
Secondly, our results emphasize that long-term persistence to treatment remains a challenge in spite of the best efforts. A recent systematic review showed that even in the context of randomized trials the effect of various interventions to increase adherence to statins is small at best (5). Nevertheless, our results urge health professionals to reinforce compliance to statins in their patients who are more likely to benefit from taking regularly their medication e.g. those at higher risk of cardiovascular diseases (CVD). Indeed, family physicians have a central role in inter-professional care at facilitating outreach approaches for optimizing adherence to medication and at monitoring results. Adherence to non-statin preventive options, including healthy diet, smoking cessation and regular physical activity, should also be strongly emphasized. Despite likewise challenging, these measures carry positive impacts on many other aspects of health and have better chances at improving global health and well-being in general (24, 25) .
Our study bears limitations. First, we limited our analysis to the RCTs selected in the Cochrane review, which included studies with <10% of patients with a history of CVD. For instance, including studies with marginally more such patients as in the ALLHAT-LLT (26) (15%) and ASCOT-LLA (27) (18%) RCTs would impact the results further away from a real primary prevention perspective. Second, the categorization of RCTs by the level of CHD risk of their study populations can be criticized as it was done post hoc. Eight of the nine RCTs could be clearly categorized on the basis of the CHD incidence rates in their control group. This criterion was not sufficient, however, to put the PHYLLIS study (17) in the higher risk category although it only included patients with uncontrolled or untreated hypertension. Nevertheless, classifying this study in one or the other category did not change our results significantly as its sample size was small compared to the others. The labels 'lower' and 'higher' CHD risk used in our classification of RCTs could roughly correspond to low (CHD event rate lower than 7% over 10 years) and moderate (CHD event rates between 12% and 16% over 10 years) CV risk using the Framingham model. This is indicative only as no direct relation can be made with the Framingham CV-risk estimation because it includes more manifestations of CVD (some at high risk of biased assessment) than the more robust definition of CHD used in this study. Future meta-analyses should plan a priori a strategy to stratify the analyses based on the baseline CHD/CV risk of the study populations included. Third, to strengthen the homogeneity of the study results and the robustness of our analysis, we chose to exclude healthrelated services and clinically subjective outcomes, such as hospitalizations for angina, and coronary intervention procedures, which are considered 'soft' outcomes (28) . This was a departure from the Cochrane review with the consequence that it reduced the number of eligible RCTs entered in our analysis making the results not directly comparable to those published (1, 6) .
The estimation of NNTs also bears limitations. First, weighted average of NNTs had large CI due to the low event counts. Their range, however, did not overlap between the two CHD-risk categories. Second, persistence-adjusted NNT, depends for its calculation on the choice of a realistic value for persistence with statin treatment in real-life. The 65% used in our analysis is consistent with current observations in the population of the province of Quebec but does not account for incomplete adherence to prescription (80% or more of the prescriptions filled) estimated at 53% in that cohort of new statin users followed over 5 years (12) . Accounting for adherence would further increase the NNT. Third, although adjusted NNT values were 15%-25% larger than their unadjusted equivalent, they still may represent an underestimation of the real number of individuals to be exposed to a statin as it does not account for other factors such as lower effectiveness of statins in new (incident) compared to former (prevalent) users (often included in RCTs) or for the healthy volunteer effect (study subjects healthier than population for equivalent risk) (29) .
Conclusion
The estimation of crude and persistence-adjusted 5-year NNT values for statins in primary prevention of populations at lower risk of CHD is almost three times larger than those in higher risk populations. Researchers and authors should avoid reporting combined results from all RCTs conducted in primary prevention and account for the CV risk in individual studies. As recommended in most clinical practice guidelines, primary health care professionals should estimate the CV risk of their patients in order to better orient their choice of preventive approaches since not all primary prevention patients are equal. As such, and emphasized by our results, lifestyle must be the priority over statins in low CV risk individuals. Knowledge of persistence-adjusted 5-year NNT values generates more realistic expectations of outcomes and reinforces the importance of promoting and monitoring compliance in patients at higher risk who are more likely to benefit from statins. These results may also contribute to motivate governments, other third-party payers and public health organizations to promoting non-pharmacological options such as diet and exercise as primary goals setting for CV primary prevention in low-risk populations.
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